TOMORROW’S TREATMENTS TODAY JOHN’S STORY Clinical trials are at the heart of all medical advances. For many patients they can offer new hope and opportunities when they have exhausted all current lines of treatments. PINPOINT is an Icon Investigator Initiated Trial and was a first-of-its-kind study. The Phase II study found that patients can choose an upfront treatment which can lead to cancer control, without the side effects of hormone therapy and more aggressive forms of radiation therapy treatment. The study showed that by targeting radiation at the prostate bed alone, quality of life is preserved for at least three years following treatment.
Principal Investigator: Dr Pat Bowden, MBBS, FRANZCR, Radiation Oncologist
“ THIS TREATMENT HAS HELPED ME GET MY LIFE BACK.” 34
ICON ANNUAL RESEARCH REPORT 2021
